Literature DB >> 25847637

Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007.

Warren Stevens1, Tomas J Philipson2, Zeba M Khan3, Joanna P MacEwan4, Mark T Linthicum5, Dana P Goldman6.   

Abstract

Health care spending and health outcomes vary markedly across countries, but the association between spending and outcomes remains unclear. This inevitably raises questions as to whether continuing growth in spending is justified, especially relative to the rising cost of cancer care. We compared cancer care across sixteen countries over time, examining changes in cancer spending and two measures of cancer mortality (amenable and excess mortality). We found that compared to low-spending health systems, high-spending systems had consistently lower cancer mortality in the period 1995-2007. Similarly, we found that the countries that increased spending the most had a 17 percent decrease in amenable mortality, compared to 8 percent in the countries with the lowest growth in cancer spending. For excess mortality, the corresponding decreases were 13 percent and 9 percent. Additionally, the rate of decrease for the countries with the highest spending growth was faster than the all-country trend. These findings are consistent with the existence of a link between higher cancer spending and lower cancer mortality. However, further work is needed to investigate the mechanisms that underlie this correlation. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Cost of Health Care; Developed World < International/global health studies; Health Economics; Health Spending; International/global health studies

Mesh:

Year:  2015        PMID: 25847637     DOI: 10.1377/hlthaff.2014.0634

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  6 in total

Review 1.  The Economic Promise of Delayed Aging.

Authors:  Dana Goldman
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-18       Impact factor: 6.915

2.  Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy.

Authors:  Lisa M Hess; Frank N Cinfio; Stewart Wetmore; Collin Churchill; Christopher Fausel; Amine Ale-Ali; Steven Gelwicks; Christopher A Bly; Sinem Perk; Robert W Klein
Journal:  Hosp Pharm       Date:  2016-06

Review 3.  Association Between Spending and Outcomes for Patients With Cancer.

Authors:  Meng Li; Darius N Lakdawalla; Dana P Goldman
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

4.  Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries.

Authors:  Ryan D Chow; Elizabeth H Bradley; Cary P Gross
Journal:  JAMA Health Forum       Date:  2022-05-27

Review 5.  Proton therapy for brain tumours in the area of evidence-based medicine.

Authors:  Damien C Weber; Pei S Lim; Sebastien Tran; Marc Walser; Alessandra Bolsi; Ulrike Kliebsch; Jürgen Beer; Barbara Bachtiary; Tony Lomax; Alessia Pica
Journal:  Br J Radiol       Date:  2019-05-20       Impact factor: 3.039

6.  Number of radiotherapy treatment machines in the population and cancer mortality: an ecological study.

Authors:  Daniel Medenwald; Dirk Vordermark; Christian T Dietzel
Journal:  Clin Epidemiol       Date:  2018-09-21       Impact factor: 4.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.